The Relationship of Intact Parathyroid Hormone and Ionised Calcium in Secondary Hyperparathyroidism among Hemodialysis Patients

T Sudhakar¹, Sabitha Kandi², B venugopal², K. Bhagwan Reddy³ and K. V. Ramana^4,

¹Department of Biochemistry, HOD lab services in-charge, Apollo Reach Hospital, Karimnagar, Andhra Pradesh, India

²Department of Biochemistry, Chalmeda Anandrao Institute of Medical Sciences, Karimnagar, India

³Department of Biochemistry, Prathima Institute of Medical Sciences, Karimnagar, India

⁴Department of Microbiology, Prathima Institute of Medical Sciences, Karimnagar, India

Cite this paper:
T Sudhakar, Sabitha Kandi, B venugopal, K. Bhagwan Reddy and K. V. Ramana. The Relationship of Intact Parathyroid Hormone and Ionised Calcium in Secondary Hyperparathyroidism among Hemodialysis Patients. American Journal of Clinical Medicine Research. 2014; 2(4):75-78. doi: 10.12691/ajcmr-2-4-3

Abstract

The parathyroid hormone (PTH) is a 115 amino acid precursor molecule; the intact PTH (iPTH) contains only 84 amino acids which is biologically active molecule. The PTH helps in regulation of serum calcium levels, either hyper or hypocalcaemia causes release of PTH. It regulates the serum calcium levels by increasing the flow of calcium from bone to extracellular fluid, by increasing the re-absorption of calcium from renal tubules and it also causes increased intestinal absorption of ionized calcium via Vitamin D. The iPTH is predominantly cleared in liver and kidney, the assay of iPTH is used for differently diagnosis of hypercalcaemia. The iPTH levels will be elevated if hypercalcaemia is due to exaggerated secretion of PTH otherwise it remains normal. Thus total calcium and ionized calcium levels will also be regulated by PTH. Secondary Hyper parathryoidism (SHPT) is a common complication of end stage renal disease (ESRD) in which there is hyperplasia of parathyroid gland. Thus, we conclude that there is an association of iPTH with ionized calcium in patients with SHPT and those undergoing hemodialysis. It is recommended that a by using a universal panel reference range in the assay of iPTH it is possible to minimize the complications in patients with chronic kidney disease.

Keywords:
iPTH ionized calcium SHPT hemodialysis chronic kidney disease

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Robert K. Murray, Daryl K. Granner, Peter A Mayes, Victor W. Rodwell. Harper’s Biochemistry: Hormones that regulate calcium metabolism; chapter 47; 25th edition, Mc Graw Hill Publishers; 2000; 568-569.
[2]	Armitage EK. Parathyrin (Parathyroid hormone): Metabolism and methods for assay. Clin Chem 1986; 32: 418-424.
[3]	Blind E, Schmidt – Gayak H, Scharla S, Flentje D, Fischer S, Goehring U et al.,. Two –site Assay of intact parathyroid hormone in the investigation of primary hyperparathyroidism and other disorders of calcium metabolism compared with a mid region assay. J Clin Endocrinol Metab 1988; 67: 353-60
[4]	Francis S. Greenspan, David G. Gardner. Basis and clinical Endocrinology: Mineral Metabolism and metabolic bone disease chapter 8; 6th edition, Mc Graw Hill Publishers; 2000; 277-278.
[5]	Silver J, Kilav R and Naveh-Many T. Mechanism of secondary hyperparathyroidism. American Journal of Physiology. 2002; 283 F367-376.
[6]	Buritt MF, Picrides AM. Comparative studies of total and ionized calcium in serum in normal subjects and patients with renal disorders. Mayo Clin Prac 1980; 55: 606-13.
[7]	Lenssar KMC, Vandenbergh. Ionised calcium plays a role in controlling BP during dialysis. Blood Purif 1989; 7: 233-239.
[8]	Gidenne S, Vigezzi JF, Delacour H, Damiano J, Clerc Y. Direct determination or estimated value of plasma ionized calcium: indications and limits. Ann Biol Clin (Paris). 2003:61(4): 393 -9.
[9]	Forman DT, Lorenzo L. Ionised calcium: its significance and clinical usefulness. Ann Clin Lab Sci. 1991:21(5): 297-304.
[10]	Robertson WG. Measurement of ionized calcium in body fluids – a review. Ann Clin Biochem. 1976; 13(6): 540-8.
[11]	Soong WJ, Wang HZ, Hwang B. Heparinization of blood decreases ionized calcium concentration. Zhonghua Yi Xue Za Zhi(Taipei). 1991; 47(5): 331-5.
[12]	National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42(4): (suppl 3) S1- S201 (pub med).
[13]	Kidney disease: Improving Global Outcomes (KDIGO) CKD – MBD Work group. KDIGO clinical practice guidelines for the diagnosis evaluation, prevention, and treatment of chronic kidney disease – mineral & bone disorder (CKD-MBD). Kidney Int. 2009; 76 (suppl 113) S1-S130.
[14]	Suetonia C. Palmer, Andrew Hayen, Petra Macaskill, Fabio Pellegrini, Jonathan C. Crig, et al. Serum levels of Phosphorus, Parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease. JAMA. 2011; 305(11): 1119-1127.
[15]	Carling T, Rastad J, Szabo E, Westin G & Akerstrom G. Reduced parathyroid vitamin D receptor messenger ribonucleic acid levels in primary and secondary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism. 2000; 85: 2000-2003.
[16]	Lewin E, Garfia B, Recio FL, Rodriguez M & Olgaard K. Persistent downregulation of calcium sensing receptor mRNA in rat parthyroids when severe secondary hyperparathyroidism is reversed by isogenic kidney transplantation. Journal of the American Society of Nephrology. 2002; 13: 2110-2116.
[17]	Saha H, Harmoinen A, Pietila K, Morsky P, Pasternack A. Measurement of serum ionised Vs total levels of Magnesium and calcium in hemodialysis patients. Clin Nephrol 1996; 46(5): 326-31.
[18]	Monier-Faugere, Malluche et al. Improved assessment of bone turnover by the PTH(1-84)/ large C-PTH fragments ratio in ESRD patients. Kidney International. 2001; 60:1460-1468.
[19]	Mizunashi K, Furukawa Y, Goto MM, Abe K. Sigmoidal curve shift in idiopathic hypoparatyroidism and pseudohypoparathyroidism. Am Soc Nephrology. 1998:62(4): 290-4.
[20]	Christensen MS. Radio immuno assay of human parthyroid hormone Dan Med Bull 1979; 26: 157-73.
[21]	Lepage R, Whittam S, Bertrand S, Bahsali G, D’Armour P. Superiority of dynamic over static reference intervals for intact, mid molecule and C-terminal parthyrin in evaluating calcemic disorders. Clin Chem. 1992; 38: 2129-35.
[22]	C.E. Duran, Jose Vicente Torregrosa, Y. Almaden, H. Cacalejo, J. M. Campistol, M Rodriguez. Dynamics of calcium – regulated PTH secretion in secondary hyperparathyroidism; comparison between invivo Vs invitro responses. Nefrologia 2010; 30(1): 73-77.
[23]	Brossard, Cloutier M, Roy L, Lepage R, Gascon – Barre M, D’Amor P. Accumulation of a non (1-84) molecular form of parathyroid hormone (PTH) detected b intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrino Metab 1996; 81: 3923-9.
[24]	Brossard JH, lepage R, Cardinal H, Roy L, Dorais, et al.,. Influence of glomerular filtration rate on non (1-84) Parathyroid hormone(PTH) detected by intact PTH assays. Clin Cehm 2000; 46: 697-703.
[25]	Lepage R, Roy L, Brossard JH, Rousseau L, Dorals C, Lazure C, et al.,. A non (1-84) circulating Parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998; 44: 805-9.
[26]	Rej R, Drake P. The nature of calibrators in immunoassays: are they commutable with test samples? Must they be? Scand J Clin Lab Invest Suppl 1991; 205:47-54.
[27]	Felder R, Holl RP, Martha J, Bauler G, Hellman P, Wills M, et al.,. Influence of matrix on concentrations of somatotropin measured in serum with commercial immunoradiometric assays. Clin Chem 1989; 35: 1423-6.
[28]	Tom Cantor, Zan Yang, Nicolae Caraiani and Ekambaram Ilamathi. Lack of comparability of Intact Parathyroid hormone measurements among commercial assays for End Stage renal disease patients: Implication for treatment decisions. Clin Chem. 2006; 52: (9):1771-6.
[29]	Pietila K, Morsky P, Pastemack A, Mustonen J, Koivula T. Intact PTH, ionized calcium and calcium infusion test in the evaluation of hyperparathyroidism in chronic renal failure. Nephron 1987; 47(4): 284-9.